Clinical trial • Phase III • Other
Losartan for Healthy volunteers
Phase III trial of Losartan for Healthy volunteers. 12 participants.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Healthy volunteers
- Trial Stage
- Phase III
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 01-01-2026
- First CTIS Authorization Date
- 26-02-2026
Trial design
Phase III trial across 1 site in Finland.
- Target Sample Size
- 12
Eligibility
Recruits 12 Vulnerable population not selected; no additional consent or assent information provided..
- Vulnerable Population
- Vulnerable population not selected; no additional consent or assent information provided.
Recruitment
- Planned Sample Size
- 12
- Recruitment Window Months
- 2
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 12
Finland
- Earliest CTIS Part Ii Submission Date
- 15-02-2026
- Latest Decision Or Authorization Date
- 14-04-2026
- Processing Time Days
- 58
- Number Of Sites
- 1
- Number Of Participants
- 12
Sites
- Site Name
- Varsinais-Suomen hyvinvointialue
- Department Name
- Turku University Hospital, Unit of Clinical Pharmacology
- Contact Person Name
- Aleksi Tornio
- Contact Person Email
- aleksi.tornio@utu.fi
- Number Of Participants
- 12
Sponsor
Primary sponsor
- Full Name
- Varsinais-Suomen hyvinvointialue
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Finland
Investigational products
- Investigational Product Name
- Losartan
- Active Substance
- Losartan
- Modality
- Small molecule
- Investigational Product Name
- Cephalexin
- Active Substance
- Cephalexin
- Modality
- Small molecule
Related trials
Other published trials that may interest you.